BR112023016459A2 - Métodos terapêuticos - Google Patents

Métodos terapêuticos

Info

Publication number
BR112023016459A2
BR112023016459A2 BR112023016459A BR112023016459A BR112023016459A2 BR 112023016459 A2 BR112023016459 A2 BR 112023016459A2 BR 112023016459 A BR112023016459 A BR 112023016459A BR 112023016459 A BR112023016459 A BR 112023016459A BR 112023016459 A2 BR112023016459 A2 BR 112023016459A2
Authority
BR
Brazil
Prior art keywords
therapeutic methods
present
relates
inclusive
administering
Prior art date
Application number
BR112023016459A
Other languages
English (en)
Portuguese (pt)
Inventor
W J Van't Hof Arnoud
S Coller Barry
Michael Gibson C
Original Assignee
Celecor Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celecor Therapeutics Inc filed Critical Celecor Therapeutics Inc
Publication of BR112023016459A2 publication Critical patent/BR112023016459A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/612Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727Heparin; Heparan
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112023016459A 2021-02-17 2022-02-16 Métodos terapêuticos BR112023016459A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163150301P 2021-02-17 2021-02-17
PCT/US2022/016571 WO2022177968A1 (en) 2021-02-17 2022-02-16 Therapeutic methods

Publications (1)

Publication Number Publication Date
BR112023016459A2 true BR112023016459A2 (pt) 2023-10-10

Family

ID=82931154

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023016459A BR112023016459A2 (pt) 2021-02-17 2022-02-16 Métodos terapêuticos

Country Status (10)

Country Link
US (1) US20250268902A1 (https=)
EP (1) EP4294402A4 (https=)
JP (1) JP2024507294A (https=)
KR (1) KR20230157354A (https=)
CN (1) CN117098538A (https=)
AU (1) AU2022224562A1 (https=)
BR (1) BR112023016459A2 (https=)
CA (1) CA3211215A1 (https=)
MX (1) MX2023009620A (https=)
WO (1) WO2022177968A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026019771A1 (en) * 2024-07-15 2026-01-22 Celecor Therapeutics, Inc. Zalunfiban for use in the treatment of thrombotic disorder in patients with renal impairment

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2804610B1 (en) * 2012-01-16 2018-10-31 The Rockefeller University Organic compounds
US11684622B2 (en) * 2018-06-19 2023-06-27 Celecor Therapeutics, Inc. Deuterated RUC-4

Also Published As

Publication number Publication date
WO2022177968A1 (en) 2022-08-25
EP4294402A4 (en) 2025-01-15
MX2023009620A (es) 2023-11-01
WO2022177968A9 (en) 2022-10-20
EP4294402A1 (en) 2023-12-27
JP2024507294A (ja) 2024-02-16
CA3211215A1 (en) 2022-08-25
CN117098538A (zh) 2023-11-21
KR20230157354A (ko) 2023-11-16
AU2022224562A1 (en) 2023-08-31
WO2022177968A8 (en) 2022-11-17
US20250268902A1 (en) 2025-08-28

Similar Documents

Publication Publication Date Title
MX2023000798A (es) Peptidos funcionalizados como agentes antivirales.
PH12023550160A1 (en) Combinations for the Treatment of Cancer
BR112018005454A2 (pt) administração de potencializadores de cftr deuterados
BR0109517A (pt) métodos e composições sinérgicas para tratar o cáncer
AR060089A1 (es) Tratamiento del dolor
BR0314126A (pt) Ligandos de amida acìclica e sulfonamida para o receptor de estrogênio
BRPI0407375A (pt) Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos
BR112018072339A2 (pt) tratamento de distúrbios de perda de cabelo com inibidores de jak deuterados
WO2020033838A3 (en) Treatment of egfr-mutant cancer
MX2021008010A (es) Composiciones y métodos para tratar las enfermedades del hígado graso no alcohólico (nafld).
PH12020551117A1 (en) Compositions for preventing or treating uveitis
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
BRPI0607536A2 (pt) tratamento de dor
PH12019500242A1 (en) 9-aminomethyl minocycline compounds and uses thereof
BR112022019338A2 (pt) Tratamento preventivo de enxaqueca
MX2022011240A (es) Azálidos de urea inmunomoduladores.
BR112023016459A2 (pt) Métodos terapêuticos
MX2023014898A (es) Terapia combinada anti-vhc ventajosa.
BR112021024835A2 (pt) Tratamento para sinuclenopatias
BR112022007974A2 (pt) Inibidores de ssao e uso dos mesmos
CO2024002712A2 (es) Azálidos inmunomoduladores
PH12020550549A1 (en) Compositions for preventing or treating lupus
MX2024003930A (es) Moduladores de trpml, sus composiciones y metodos de uso.
BR112023023965A2 (pt) Método terapêutico para um gato com doença renal crônica, e, agente terapêutico
PH12020551620A1 (en) Compositions for preventing or treating dry eye